SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Cantor Fitzgerald Reiterates Overweight on Reata Pharmaceuticals, Raises Price Target to $314

Cantor Fitzgerald reiterates Reata Pharmaceuticals (NASDAQ:RETA) with a Overweight and raises the price target from $250 to $314.

Benzinga · -

Cantor Fitzgerald reiterates Reata Pharmaceuticals (NASDAQ:RETA) with a Overweight and raises the price target from $250 to $314.